Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3650445 | 0.83 | PRKCI (0.51) | PRKCICHRNB4CHRNA3CHRNA7HTR1A | |
| SCHEMBL27813877 | 0.83 | PRKCI (0.51) | PRKCICHRNB4CHRNA3CHRNA7PIK3CD | |
| SCHEMBL3650131 | 0.82 | PRKCI (0.50) | PRKCICHRNB4CHRNA3CHRNA7HTR1A | |
| SCHEMBL1301002 | 0.82 | PRKCI (0.50) | PRKCICHRNB4CHRNA3CHRNA7HTR1A | |
| SCHEMBL13285567 | 0.82 | PRKCI (0.50) | PRKCICHRNB4CHRNA3CHRNA7HTR1A | |
| SCHEMBL1581550 | 0.82 | PRKCI (0.50) | PRKCICHRNB4CHRNA3CHRNA7HTR1A | |
| SCHEMBL31500185 | 0.82 | PRKCI (0.50) | PRKCICHRNB4CHRNA3CHRNA7HTR1A | |
| SCHEMBL27783403 | 0.81 | PRKCI (0.50) | PRKCICHRNB4CHRNA3CHRNA7PIK3CD | |
| SCHEMBL10595143 | 0.81 | RECQL (0.50) | PRKCICHRNB4CHRNA3CHRNA7CLK4 | |
| SCHEMBL4191589 | 0.80 | PRKCI (0.72) | PRKCICHRNB4CHRNA3CHRNA7CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| CN-109790146-A | Medical compounds | 阿尔麦克探索有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2855489-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2855489-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
| EP-2516439-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | PRKCI 2728/4885CHRNB4 1744/4885CHRNA3 1463/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | PRKCI 2728/4885CHRNB4 1744/4885CHRNA3 1463/4885 |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | REN, PKD1, NR3C2 | PRKCI 3162/4885CHRNB4 3888/4885CHRNA3 2520/4885 |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | REN, PKD1, NR3C2 | PRKCI 3031/4885CHRNB4 4373/4885CHRNA3 3116/4885 |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | PRKCI 3236/4885CHRNB4 1483/4885CHRNA3 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.